Track topics on Twitter Track topics that are important to you
BEIJING, June 29, 2017 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, announced that the proton treatment building of the Beijing Proton Medical Center officially started construction.
The Beijing Proton Medical Center is an independent proton radiotherapy institution established by Concord Medical and China-Japan Friendship Hospital, with an independent legal personality approved by the National Health and Family Planning Commission of the People's Republic of China (formerly, the Ministry of Health), and is the first proton center in Beijing constructed under international standards. After completion, it will be among the first batch of clinical dedicated proton centers with a formal configuration license. In addition, the installation of the IBA Proton Therapy System is expected to start in January 2018. The installation of the first treatment room will be completed in the first quarter of 2019, and will be open for operation. In the first quarter of 2020, we can expect four treatment rooms will be all open for operation.
Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented, "I am pleased to see that, after years of efforts and with the strong support of our partners, the proton treatment building of the Beijing Proton Medical Center has finally started construction. The commencement of this project is an important milestone in the overall strategic development of Concord Medical, and is also the achievement of the sincere cooperation between China-Japan Friendship Hospital and us. I hope the project will proceed smoothly. We will make every effort to ensure that the project is completed on time, with emphasis on quality and safety. Proton therapy, a kind of precise radiation therapy treatment using proton beam for tumor, is a mature, and currently the most advanced, form of radiation therapy. I believe that the completion of the proton center not only will promote the development of cancer radiotherapy in China, but will also help Chinese cancer patients in their recovery."
About Beijing Proton Medical Center
The Beijing Proton Medical Center is located in the northeast corner of China-Japan Friendship Hospital at 2 Yinghua Dongjie, Chaoyang District, Beijing. It covers an area of about 5,000 square meters and has a construction area of nearly 13,000 square meters. The center will be equipped with 50 beds, four proton therapy rooms employing the IBA proton therapy system (including three gantry-rooms and one fix-beam room) and a linear accelerator treatment room, as well as an outpatient department, wards and other auxiliary facilities.
Safe Harbor Statement
This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
For more information, please contact:
Concord Medical Services
Ms. Carol TIAN (Chinese and English)
+86 10 5903 6688 (ext. 608)
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/concord-medical-announces-construction-of-proton-treatment-building-of-beijing-proton-medical-center-300481838.html
SOURCE Concord Medical Services Holdings LimitedNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...